Azurity Pharmaceuticals, Inc.
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
Previously recorded as Cutispharma, Inc. (to 2020)
0
Ending by 2030
Dec 2033
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 20, 2026The maintenance fee for Pharmaceutical Compositions of Cabozantinib (US 11,679,105) comes due Dec 20, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 3 fees due Jan 9 to 25, 2027 · next Jan 9
- 2 fees due Mar 10 to 19, 2027 · next Mar 10
- 5 fees due Apr 3 to 29, 2027 · next Apr 3
- 3 fees due May 7 to 21, 2027 · next May 7
- 2 fees due Jun 3 to 19, 2027 · next Jun 3
- 2 fees due Jul 16 to 23, 2027 · next Jul 16
- 1 fee due Aug 27, 2027The maintenance fee for Compositions and Kits for Omeprazole Suspension (US 11,911,473) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
- 4 fees due Sep 3 to 26, 2027 · next Sep 3
Recent changes
- 3 of the patents on this record were granted since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US D836,772 | Syringe In force · High confidence | In force | High confidence | |
| US 9,919,007 | Dual Use Oral Pharmaceutical Composition Tablets of Sulfate Salts and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US D851,757 | Syringe In force · High confidence | In force | High confidence | |
| US 10,493,028 | Composition and Method for Vancomycin Oral Liquid In force · Medium confidence | In force | Medium confidence | |
| US 10,688,046 | Composition and Method for Vancomycin Oral Liquid In force · Medium confidence | In force | Medium confidence | |
| US 10,959,946 | Composition and Method for Vancomycin Oral Liquid In force · Medium confidence | In force | Medium confidence | |
| US 10,959,947 | Composition and Method for Vancomycin Oral Liquid In force · Medium confidence | In force | Medium confidence | |
| US 10,959,948 | Composition and Method for Vancomycin Oral Liquid In force · Medium confidence | In force | Medium confidence | |
| US 10,959,949 | Composition and Method for Vancomycin Oral Liquid In force · Medium confidence | In force | Medium confidence | |
| US 11,638,692 | Composition and Method for Vancomycin Oral Liquid In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 120: 6 patents in force now held by others · 1 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 13 abandoned